Subtopic Deep Dive
Glucocerebrosidase Mutations in Parkinson's
Research Guide
What is Glucocerebrosidase Mutations in Parkinson's?
Glucocerebrosidase (GBA) mutations represent the strongest common genetic risk factor for Parkinson's disease, impairing lysosomal function and promoting alpha-synuclein aggregation.
Heterozygous GBA mutations increase Parkinson's disease risk and accelerate cognitive decline (Cilia et al., 2016, 399 citations). Studies using iPSC-derived neurons reveal autophagic defects and calcium dysregulation in GBA-PD patients (Schöndorf et al., 2014, 531 citations). Over 20 papers since 2010 link GBA variants to earlier onset and severe phenotypes (Gan-Or et al., 2015, 352 citations).
Why It Matters
GBA mutations in Parkinson's highlight lysosomal dysfunction as a therapeutic target, with ambroxol enhancing glucocerebrosidase activity in mutation-linked cells (McNeill et al., 2014, 311 citations). Clinical trials test ambroxol in GBA-PD patients, showing potential to slow progression (Mullin et al., 2020, 314 citations). Genotype-phenotype studies guide personalized risk assessment and counseling (Cilia et al., 2016). These links extend lysosomal therapies from Gaucher disease to neurodegeneration, impacting millions with Parkinson's.
Key Research Challenges
Genotype-Phenotype Variability
Severe vs mild GBA mutations differentially affect Parkinson's onset and progression (Gan-Or et al., 2015, 352 citations). Distinguishing risk levels remains challenging for counseling. Larger cohorts are needed to refine predictions (Cilia et al., 2016).
Mechanistic Alpha-Synuclein Link
GBA defects elevate extracellular alpha-synuclein via ER stress and autophagy failure in iPSC neurons (Fernandes et al., 2016, 350 citations). Exact pathways require clarification. Mutant GBA alters synuclein processing directly (Cullen et al., 2011, 305 citations).
Therapeutic Efficacy Testing
Ambroxol boosts lysosomal activity but trial outcomes vary by mutation status (Mullin et al., 2020). Measuring enzymatic deficits in vivo is difficult (Alcalay et al., 2015, 387 citations). Validating chaperones across mutation types persists as an issue.
Essential Papers
Parkinson's disease
Bastiaan R. Bloem, Michael S. Okun, Christine Klein · 2021 · The Lancet · 3.2K citations
Lysosomes as a therapeutic target
Srinivasa Reddy Bonam, Fengjuan Wang, Sylviane Muller · 2019 · Nature Reviews Drug Discovery · 718 citations
iPSC-derived neurons from GBA1-associated Parkinson’s disease patients show autophagic defects and impaired calcium homeostasis
David C. Schöndorf, Massimo Aureli, Fiona E. McAllister et al. · 2014 · Nature Communications · 531 citations
Survival and dementia in <scp> <i>GBA</i> </scp> ‐associated Parkinson's disease: <scp>T</scp> he mutation matters
Roberto Cilia, Sara Tùnesi, Giorgio Marotta et al. · 2016 · Annals of Neurology · 399 citations
Objective The objective of this work was to investigate survival, dementia, and genotype‐phenotype correlations in patients with Parkinson's disease (PD) with and without mutations on the glucocere...
Glucocerebrosidase activity in Parkinson’s disease with and without<i>GBA</i>mutations
Roy N. Alcalay, Oren Levy, Cheryl Waters et al. · 2015 · Brain · 387 citations
Glucocerebrosidase (GBA) mutations have been associated with Parkinson's disease in numerous studies. However, it is unknown whether the increased risk of Parkinson's disease in GBA carriers is due...
Parkinson's disease age at onset genome‐wide association study: Defining heritability, genetic loci, and α‐synuclein mechanisms
Cornelis Blauwendraat, Karl Heilbron, Costanza L. Vallerga et al. · 2019 · Movement Disorders · 362 citations
Abstract Background Increasing evidence supports an extensive and complex genetic contribution to PD. Previous genome‐wide association studies (GWAS) have shed light on the genetic basis of risk fo...
Differential effects of severe vs mild <i>GBA</i> mutations on Parkinson disease
Ziv Gan‐Or, Idan Amshalom, Laura L. Kilarski et al. · 2015 · Neurology · 352 citations
These data demonstrate that mild and severe heterozygous GBA mutations differentially affect the risk and the AAO of PD. Our results have important implications for genetic counseling and clinical ...
Reading Guide
Foundational Papers
Start with Schöndorf et al. (2014, 531 citations) for iPSC evidence of lysosomal defects; McNeill et al. (2014, 311 citations) on ambroxol; Cullen et al. (2011, 305 citations) for alpha-synuclein processing.
Recent Advances
Cilia et al. (2016, 399 citations) on mutation-specific dementia; Mullin et al. (2020, 314 citations) ambroxol trial; Blauwendraat et al. (2019, 362 citations) GWAS age-at-onset.
Core Methods
iPSC neuron differentiation for autophagy/calcium assays (Schöndorf et al., 2014); glucocerebrosidase activity measurement (Alcalay et al., 2015); cohort genotyping for survival analysis (Cilia et al., 2016).
How PapersFlow Helps You Research Glucocerebrosidase Mutations in Parkinson's
Discover & Search
Research Agent uses searchPapers and exaSearch to find GBA-PD papers like 'Survival and dementia in GBA-associated Parkinson's disease' by Cilia et al. (2016), then citationGraph reveals 399 citing works on mutation severity, and findSimilarPapers uncovers related iPSC studies.
Analyze & Verify
Analysis Agent applies readPaperContent to extract enzymatic activity data from Alcalay et al. (2015), verifies claims with CoVe against Schöndorf et al. (2014), and runs PythonAnalysis on mutation frequency stats using pandas for GWAS heritability from Blauwendraat et al. (2019), with GRADE scoring evidence strength.
Synthesize & Write
Synthesis Agent detects gaps in ambroxol trials post-Mullin et al. (2020), flags contradictions in GBA severity effects, while Writing Agent uses latexEditText, latexSyncCitations for GBA-PD reviews, latexCompile for manuscripts, and exportMermaid diagrams lysosomal-alpha-synuclein pathways.
Use Cases
"Analyze survival curves from Cilia et al. 2016 GBA-PD cohort with stats."
Research Agent → searchPapers(Cilia) → Analysis Agent → readPaperContent → runPythonAnalysis(pandas survival plot, Kaplan-Meier stats) → matplotlib figure of dementia risk by mutation severity.
"Draft LaTeX review on GBA mutations and alpha-synuclein with citations."
Synthesis Agent → gap detection(Gan-Or 2015, Fernandes 2016) → Writing Agent → latexEditText(intro), latexSyncCitations(10 GBA papers), latexCompile → PDF review section with synced refs.
"Find GitHub code for iPSC GBA-PD calcium imaging analysis."
Research Agent → paperExtractUrls(Schöndorf 2014) → Code Discovery → paperFindGithubRepo → githubRepoInspect → Python scripts for autophagy quantification from neuron data.
Automated Workflows
Deep Research workflow scans 50+ GBA-PD papers via searchPapers, structures reports on mutation risks with GRADE grading from Cilia et al. (2016). DeepScan applies 7-step CoVe to verify ambroxol mechanisms in Mullin et al. (2020) trials. Theorizer generates hypotheses on lysosomal targets from Schöndorf et al. (2014) iPSC defects.
Frequently Asked Questions
What defines GBA mutations in Parkinson's?
Heterozygous GBA1 mutations, causing glucocerebrosidase deficiency, raise Parkinson's risk via lysosomal impairment (Schöndorf et al., 2014).
What methods study GBA-PD mechanisms?
iPSC-derived neurons model autophagic and calcium defects (Schöndorf et al., 2014); enzymatic assays measure activity (Alcalay et al., 2015).
What are key papers on GBA-PD?
Schöndorf et al. (2014, 531 citations) on iPSC defects; Cilia et al. (2016, 399 citations) on survival/dementia; Gan-Or et al. (2015, 352 citations) on mutation severity.
What open problems exist?
Optimal therapies for mild vs severe mutations; in vivo validation of alpha-synuclein links; personalized screening strategies.
Research Lysosomal Storage Disorders Research with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Glucocerebrosidase Mutations in Parkinson's with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers